Journal of Clinical Endocrinology & Metabolism, Vol 63, 1361-1364, Copyright © 1986 by Endocrine Society

ARTICLES

Pharmacokinetic properties of testosterone propionate in normal men

M Fujioka, Y Shinohara, S Baba, M Irie and K Inoue

The pharmacokinetic characteristics of testosterone propionate were studied in normal men after a single im dose of 25 mg testosterone propionate-19,19,19-d3. Plasma levels of testosterone propionate- 19,19,19-d3, its active metabolite testosterone-19,19,19-d3, and endogenous testosterone were measured by gas chromatography-mass spectrometry. Testosterone propionate-19,19,19-d3 was gradually transferred from the im injection site to the systemic circulation. The plasma levels of testosterone propionate-19,19,19-d3 were maintained at 2-4 ng/ml between 3 and 36 h after administration. Plasma testosterone- 19,19,19-d3 levels were maintained above the physiological testosterone level for 48 h, while plasma levels of endogenous testosterone changed little.

This article has been cited by other articles:

				J. M. Fitts, R. M. Klein, and C. A. Powers Comparison of Tamoxifen and Testosterone Propionate in Male Rats: Differential Prevention of Orchidectomy Effects on Sex Organs, Bone Mass, Growth, and the Growth Hormone-IGF-I Axis J Androl, July 1, 2004; 25(4): 523 - 534. [Abstract] [Full Text] [PDF]

				C. Wang, D. H. Catlin, B. Starcevic, A. Leung, E. DiStefano, G. Lucas, L. Hull, and R. S. Swerdloff Testosterone Metabolic Clearance and Production Rates Determined by Stable Isotope Dilution/Tandem Mass Spectrometry in Normal Men: Influence of Ethnicity and Age J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2936 - 2941. [Abstract] [Full Text] [PDF]

				D. M. Shackleford, W. A. Faassen, N. Houwing, H. Lass, G. A. Edwards, C. J. H. Porter, and W. N. Charman Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 925 - 933. [Abstract] [Full Text] [PDF]

				R. A. Anderson and D. T. Baird Male Contraception Endocr. Rev., December 1, 2002; 23(6): 735 - 762. [Abstract] [Full Text] [PDF]

				A. Strawford, T. Barbieri, M. Van Loan, E. Parks, D. Catlin, N. Barton, R. Neese, M. Christiansen, J. King, and M. K. Hellerstein Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial JAMA, April 14, 1999; 281(14): 1282 - 1290. [Abstract] [Full Text] [PDF]

				H. Vierhapper, P. Nowotny, and W. Waldhausl Determination of Testosterone Production Rates in Men and Women Using Stable Isotope/Dilution and Mass Spectrometry J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1492 - 1496. [Abstract] [Full Text] [PDF]

				C. F. Minto, C. Howe, S. Wishart, A. J. Conway, and D. J. Handelsman Pharmacokinetics and Pharmacodynamics of Nandrolone Esters in Oil Vehicle: Effects of Ester, Injection Site and Injection Volume J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 93 - 102. [Abstract] [Full Text]